AbbVie Stock Climbs a Wall of Humira Worry. There’s Still Time to Buy. View Larger Image Max Wasserman shares why he views AbbVie as a “great company that’s going to be a solid performer” even as it waits for drugs, other than Humira, to mature. Read Article > By Max Wasserman|2022-12-02T20:18:27+00:00December 2nd, 2022|In the Press| Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail Related Posts